Sandoz reports third-quarter and nine-month 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launches Generics growth acceleration driven by Europe Third-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD) Nine-month net sales of USD 7.6 billion, [...]